Skip to main content
. Author manuscript; available in PMC: 2024 Apr 28.
Published in final edited form as: Antiviral Res. 2020 Jul 6;181:104858. doi: 10.1016/j.antiviral.2020.104858

Fig. 3. SC administration of favipiravir results in significant concentrations of favipiravir in the serum.

Fig. 3.

At indicated timepoints for animals receiving once-daily (A) or twice-daily (B) favipiravir treatment serum was collected and concentration of favipiravir quantified by LC-MS. On days 1 and 3 PI, blood was collected at 8 or 12 h post-treatment, + 8H or +12H respectively. ND = not done. N = 6 per timepoint. Limit of detection was 0.01 μg/mL.